US Stock MarketDetailed Quotes
OCX OncoCyte
- 2.3808
- -0.0542-2.23%
Trading Nov 29 11:10 ET
40.08MMarket Cap-537P/E (TTM)
2.5000High2.3200Low178.81KVolume2.4000Open2.4350Pre Close434.70KTurnover2.62%Turnover RatioLossP/E (Static)16.84MShares3.980052wk High4.13P/B16.28MFloat Cap2.000052wk Low--Dividend TTM6.84MShs Float204.8000Historical High--Div YieldTTM7.39%Amplitude2.0000Historical Low2.4310Avg Price1Lot Size
OncoCyte Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -73.19%115K | -77.54%104K | -40.74%176K | 56.89%1.5M | 14.60%314K | 540.30%429K | 95.36%463K | -21.84%297K | -56.41%958K | 114.12%274K |
| Operating revenue | -73.19%115K | -77.54%104K | -40.74%176K | 56.89%1.5M | 14.60%314K | 540.30%429K | 95.36%463K | -21.84%297K | -56.41%958K | 114.12%274K |
| Cost of revenue | -64.09%65K | -71.73%54K | -4.53%274K | 11.68%1.09M | 43.19%431K | -46.13%181K | -7.28%191K | 115.79%287K | 25.45%976K | 106.63%301K |
| Gross profit | -79.84%50K | -81.62%50K | -1,080.00%-98K | 2,394.44%413K | -333.33%-117K | 192.19%248K | 777.42%272K | -95.95%10K | -101.27%-18K | -101.04%-27K |
| Operating expense | 19.69%6.43M | -9.17%5.71M | -8.76%5.69M | -20.82%22.83M | -17.71%4.94M | -23.54%5.37M | -20.30%6.29M | -21.29%6.23M | 13.40%28.83M | 183.21%6M |
| Selling and administrative expenses | 13.35%3.61M | -15.43%3.26M | -14.32%3.52M | -37.14%13.54M | -48.28%2.39M | -42.64%3.18M | -29.24%3.86M | -30.54%4.11M | 5.60%21.53M | 244.15%4.62M |
| -Selling and marketing expense | 123.38%172K | 81.48%147K | 90.91%84K | 1,717.65%309K | 1,428.57%107K | 2,466.67%77K | 3,950.00%81K | 780.00%44K | 240.00%17K | 100.27%7K |
| -General and administrative expense | 10.62%3.44M | -17.51%3.11M | -15.46%3.44M | -38.52%13.23M | -50.52%2.28M | -44.00%3.11M | -30.70%3.77M | -31.23%4.06M | 5.54%21.52M | 828.08%4.62M |
| Research and development costs | 28.92%2.82M | 0.74%2.45M | 1.97%2.17M | 27.30%9.29M | 84.83%2.55M | 48.44%2.19M | -0.37%2.44M | 5.98%2.13M | 45.00%7.3M | 134.41%1.38M |
| Operating profit | -24.51%-6.38M | 5.90%-5.66M | 7.04%-5.79M | 22.30%-22.42M | 16.14%-5.06M | 29.77%-5.12M | 23.44%-6.02M | 18.88%-6.22M | -20.18%-28.85M | -161.43%-6.03M |
| Net non-operating interest income expense | -121.43%-31K | 42.86%-8K | -36.36%-15K | 37.35%-52K | 27.78%-13K | 0.00%-14K | 33.33%-14K | 63.33%-11K | 60.29%-83K | 57.14%-18K |
| Non-operating interest expense | 121.43%31K | -42.86%8K | 36.36%15K | -37.35%52K | --13K | --14K | --14K | -63.33%11K | -60.29%83K | ---- |
| Other net income (expense) | -423.03%-7.09M | 149.59%1.14M | -127.29%-3.33M | -123.11%-2.39M | -82.95%-10.92M | -124.70%-1.36M | -135.30%-2.3M | 184.24%12.19M | 136.03%10.32M | 76.18%-5.97M |
| Gain on sale of security | ---- | ---- | ---- | 87.05%-61K | -592.86%-69K | 44.38%-89K | -580.00%-24K | 136.67%121K | -305.68%-471K | 173.68%14K |
| Special income (charges) | -412.56%-7.14M | 145.30%1.03M | -128.83%-3.48M | -125.05%-2.72M | -97.94%-11.12M | -124.95%-1.39M | -136.50%-2.28M | 159.32%12.07M | 137.99%10.86M | 77.53%-5.62M |
| -Less：Restructuring and merger&acquisition | 1,808.13%7.14M | -145.30%-1.03M | 118.09%3.31M | 81.99%-5.32M | 185.18%11.13M | 92.51%-418K | 136.50%2.28M | -293.19%-18.31M | -199.40%-29.54M | -152.24%-13.06M |
| -Less:Impairment of capital assets | --0 | --0 | --0 | -63.84%6.76M | -70.70%5.47M | --0 | --0 | --4.95M | --18.68M | --18.68M |
| -Write off | --0 | --0 | -86.83%169K | ---- | ---- | --1.81M | --0 | --1.28M | ---- | ---- |
| -Gain on sale of property,plant,equipment | ---- | ---- | ---- | ---1.28M | ---- | ---- | ---- | ---- | --0 | --0 |
| Other non- operating income (expenses) | -58.27%53K | 11,100.00%110K | 15,400.00%153K | 745.90%394K | 173.70%269K | 104.84%127K | -100.36%-1K | 97.22%-1K | -64.86%-61K | -676.60%-365K |
| Income before tax | -107.94%-13.49M | 45.64%-4.53M | -253.20%-9.13M | -33.54%-24.86M | -33.08%-15.99M | -256.93%-6.49M | -510.92%-8.33M | 274.60%5.96M | 64.80%-18.61M | 21.46%-12.02M |
| Income tax | 0 | 0 | ||||||||
| Net income | -107.94%-13.49M | 45.64%-4.53M | -400.99%-9.13M | 61.89%-27.78M | 64.44%-15.99M | 30.47%-6.49M | -0.40%-8.33M | 129.47%3.03M | -13.74%-72.9M | -25.34%-44.98M |
| Net income continuous Operations | -107.94%-13.49M | 45.64%-4.53M | -253.20%-9.13M | -33.54%-24.86M | -33.08%-15.99M | -256.93%-6.49M | -510.92%-8.33M | 274.60%5.96M | 57.32%-18.61M | 21.96%-12.02M |
| Net income discontinuous operations | --0 | --0 | --0 | 94.61%-2.93M | --0 | --0 | --0 | 57.46%-2.93M | -165.00%-54.29M | ---32.96M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | -107.94%-13.49M | 45.64%-4.53M | -400.99%-9.13M | 61.89%-27.78M | 64.44%-15.99M | 30.47%-6.49M | -0.40%-8.33M | 129.47%3.03M | -13.74%-72.9M | -25.34%-44.98M |
| Preferred stock dividends | -10.43%206K | 81.15%942K | 264.60%824K | 63.89%118K | 230K | 520K | 226K | |||
| Other preferred stock dividends | 0 | -70.47%57K | 0 | 198K | 193K | 406K | ||||
| Net income attributable to common stockholders | -101.78%-13.49M | 46.93%-4.59M | -489.45%-9.34M | 60.88%-28.72M | 64.17%-16.2M | 30.54%-6.69M | -3.25%-8.64M | 123.29%2.4M | -14.55%-73.42M | -25.97%-45.2M |
| Basic earnings per share | -20.99%-0.98 | 66.36%-0.36 | -382.50%-1.13 | 71.70%-3.75 | 74.22%-2.07 | 50.00%-0.81 | 27.70%-1.07 | 118.18%0.4 | 7.99%-13.25 | -2.95%-8.03 |
| Diluted earnings per share | -20.99%-0.98 | 66.36%-0.36 | -382.50%-1.13 | 71.70%-3.75 | 74.22%-2.07 | 50.00%-0.81 | 27.70%-1.07 | 118.18%0.4 | 7.99%-13.25 | -2.95%-8.03 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data